In addition, other FDA-approved ADCs comprise gemtuzumab ozogamicin targeting CD33, brentuximab vedotin targeting CD30, inotuzumab ozogamicin targeting CD22, polatuzumab vedotin targeting CD79b, belantamab mafodotin targeting BCMA, loncastuximab tesirine targeting CD19, and moxetumomab pasudotox targeting CD22 for hairy cell leukemia, although the latter has since been withdrawn from the US market (https://www.fda.gov/, accessed July 2025) [100]. The gene discussed is CD22; the disease is hairy cell leukemia.